A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer

Inclusion Criteria:

- Untreated metastatic adenocarcinoma of the pancreas (AJCC Stage IV)

- Subjects with unresectable pancreatic cancer who have had surgery are eligible if
fully recovered and greater than 30 days have elapsed since the surgery.

Subjects with a history of pancreatoduodenectomy are eligible provided that there is
radiographically documented disease recurrence.

- Men or women ≥ 18 years of age

- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

- Adequate hematologic, hepatic, renal and coagulation function

- Amylase and lipase ≤ 2.0 x ULN

- Adequately controlled type 1 or 2 diabetic subjects

Exclusion Criteria:

- Islet cell, acinar cell carcinoma, non-adenocarcinoma (eg, lymphoma, sarcoma, etc),
adenocarcinoma originated from biliary tree or cystadenocarcinoma

- Known central nervous system metastases

- Uncontrolled cardiac disease or any other co-morbid disease that would increase the
risk of toxicity

- Adjuvant chemotherapy or chemoradiotherapy